Abstract 1986P
Background
To date no specific evidence exists on the impact of COVID-19 in pts with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and chemotherapy on COVID-19 morbidity and mortality in this specific population.
Methods
We described COVID-19 morbidity and mortality among pts with STS across “Omicron” (15/12/21-31/01/22), “Pre-vaccination” (27/02/20-30/11/20) and “Alpha-Delta” phase (01/12/20-14/12/21) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR28) and COVID-19 severity were described according to the SARS-CoV-2 vaccination status, whilst the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders.
Results
Out of 3820 pts, 97 pts with STS were included. The median age at COVID-19 diagnosis was 56 years, with 65 pts (67%) aged <65 years old and 65 pts had low comorbidity burden (67%). In total, 36 pts were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications and 32.3% of hospitalizations due to COVID-19. CFR28 (29,5%, 21.4%, 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated pts demonstrated numerically improved CFR28 (16.7% vs 27.7%) and COVID-19 morbidity compared with unvaccinated pts. Pts who were on chemotherapy experienced comparable CFR28 (19.4% vs 26.0%, p=0.4803), hospitalizations (50.0% vs 44.4%, p=0.6883), complication rates (30.6% vs 34.0%, p=0.7381) and oxygen therapy requirement (28.1% vs 40.0%, p=0.2755) compared to those who were not on anticancer therapy at COVID-19, findings further confirmed by the IPTW-fitted multivariable analysis.
Conclusions
This is the first study to demonstrate the time-dependent improvement of COVID-19 outcomes in pts with STS. Exposure to chemotherapy does not impact on COVID-19 morbidity/mortality and SARS-CoV-2 vaccination confers protection against adverse outcome from COVID-19 in this patient population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15